Pharvaris NV - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Pharvaris NV Company

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Pharvaris NV Info



Ticker SymbolPHVS

Company namePharvaris NV

IPO dateFeb 05, 2021

CEOMr. Berndt Modig, CPA

Number of employees- -

Security typeOrdinary Share

Fiscal year-endFeb 05

AddressEmmy Noetherweg 2

CityLEIDEN

Stock exchangeNASDAQ Global Select Consolidated

CountryNetherlands

Postal code2333 BK

Phone31712036410

Websitehttps://pharvaris.com/

Ticker SymbolPHVS

IPO dateFeb 05, 2021

CEOMr. Berndt Modig, CPA

Company Executives of Pharvaris NV



Name

Name/Position

Position

Shareholding

Change

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

--

Dr. Anne Marie De Jonge Schuermans, Ph.D.

Non-Executive Director

--

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

--

Dr. Morgan Conn, Ph.D.

Chief Business Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Tue, Aug 19

Shareholders

Shareholder Types

Shareholders

Proportion

General Atlantic LLC

11.76%

Fidelity Management & Research Company LLC

8.47%

Foresite Capital Management, LLC

6.89%

VenBio Partners LLC

6.70%

Viking Global Investors LP

5.70%

Other

60.49%

Shareholders

Proportion

General Atlantic LLC

11.76%

Fidelity Management & Research Company LLC

8.47%

Foresite Capital Management, LLC

6.89%

VenBio Partners LLC

6.70%

Viking Global Investors LP

5.70%

Other

60.49%

Shareholder Types

Shareholders

Proportion

Private Equity

25.72%

Investment Advisor

16.09%

Hedge Fund

14.25%

Venture Capital

13.60%

Investment Advisor/Hedge Fund

6.29%

Individual Investor

5.32%

Research Firm

0.08%

Bank and Trust

0.04%

Pension Fund

0.03%

Other

18.58%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

115

48.75M

76.10%

-1.83M

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

83

52.08M

96.43%

-141.66K

2024Q1

76

49.63M

98.30%

-831.88K

2023Q4

69

47.76M

94.74%

+8.60M

2023Q3

54

36.05M

91.51%

-2.92M

2023Q2

53

35.78M

91.11%

+3.65M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

General Atlantic LLC

7.53M

11.76%

--

Jun 30, 2025

Fidelity Management & Research Company LLC

5.42M

8.47%

+27.02K

+0.50%

Jun 30, 2025

Foresite Capital Management, LLC

4.41M

6.89%

--

Jun 30, 2025

VenBio Partners LLC

4.29M

6.7%

--

Jun 30, 2025

Viking Global Investors LP

3.65M

5.7%

--

Jun 30, 2025

EQT Life Sciences

3.56M

5.55%

--

Apr 01, 2025

Bain Capital Life Sciences Investors, LLC

3.30M

5.16%

--

Jun 30, 2025

VR Adviser, LLC

2.05M

3.2%

-1.07M

-34.22%

Jun 30, 2025

Deerfield Management Company, L.P.

2.02M

3.15%

--

Jun 30, 2025

Commodore Capital LP

1.91M

2.98%

--

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

Virtus LifeSci Biotech Clinical Trials ETF

0.98%

ALPS Medical Breakthroughs ETF

0.69%

iShares MSCI Netherlands ETF

0.21%

iShares MSCI Europe Small-Cap ETF

0.03%

SPDR S&P International Small Cap ETF

0.03%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0.01%

iShares MSCI EAFE Small-Cap ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0%

Avantis International Small Cap Equity ETF

0%

First Trust IPOX Europe Equity Opportunities ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.98%

ALPS Medical Breakthroughs ETF

Proportion0.69%

iShares MSCI Netherlands ETF

Proportion0.21%

iShares MSCI Europe Small-Cap ETF

Proportion0.03%

SPDR S&P International Small Cap ETF

Proportion0.03%

Xtrackers MSCI Eurozone Hedged Eqty ETF

Proportion0.01%

iShares MSCI EAFE Small-Cap ETF

Proportion0.01%

Fidelity Nasdaq Composite Index ETF

Proportion0%

Avantis International Small Cap Equity ETF

Proportion0%

First Trust IPOX Europe Equity Opportunities ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data